Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Milestone Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing etripamil, a novel calcium channel blocker administered as an intranasal spray for rapid termination of paroxysmal supraventricular tachycardia (PSVT). The company has no commercial revenue and is entirely dependent on clinical trial success and eventual FDA approval, with cash runway being the primary near-term concern given negative operating cash flow of approximately $30M annually.
Milestone operates a classic clinical-stage biotech model with no current revenue generation. The company's value proposition centers on etripamil's potential as a patient-administered treatment for PSVT episodes, eliminating emergency room visits (current standard of care costs $3,000-$5,000 per episode). Monetization pathway requires successful Phase 3 trial completion, FDA approval (estimated 2027-2028 timeframe based on typical review cycles), and either direct commercialization in the US or partnership/licensing deals. Pricing power would be moderate given competition from existing treatments (adenosine, vagal maneuvers) but differentiated by self-administration convenience.
Phase 3 clinical trial data readouts for etripamil in PSVT (NODE-1 and NODE-2 trial results)
FDA regulatory milestone announcements (NDA submission, acceptance, approval decisions)
Cash runway updates and equity financing announcements (critical given $30M annual burn rate)
Partnership or licensing deal announcements for commercialization rights
Competitive developments in PSVT treatment landscape or alternative calcium channel blocker programs
Binary clinical trial risk - Phase 3 failure would likely result in near-total equity value destruction given single-asset focus on etripamil
FDA regulatory risk including potential requirement for additional trials, safety concerns, or approval delays beyond 2027-2028 estimated timeline
Reimbursement uncertainty - payer willingness to cover self-administered PSVT treatment versus lower-cost ER-based adenosine remains unproven
Alternative PSVT treatments in development including other patient-administered formulations or novel mechanism approaches
Established treatment paradigm inertia - physicians and patients may prefer proven ER-based protocols despite convenience disadvantages
Potential for large pharma to develop competing calcium channel blocker formulations with superior delivery mechanisms or faster onset
Dilution risk from future equity raises - with $30M annual cash burn and $100M market cap, significant shareholder dilution likely before commercialization
Going concern risk if unable to secure additional financing within 12-18 month runway based on current cash position
Debt/Equity ratio of 2.79 suggests existing leverage that could complicate future financing negotiations or require asset sales/licensing deals on unfavorable terms
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as they have no commercial operations. However, severe recessions can impact ability to raise capital and affect M&A/partnership valuations. PSVT treatment demand would be non-discretionary regardless of economic conditions.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (etripamil revenue not expected until 2028+). Higher rates also increase opportunity cost of holding cash-burning pre-revenue assets versus fixed income. Financing costs for future debt raises would increase, though company currently relies on equity financing. The 8.24x current ratio suggests adequate near-term liquidity, but sustained high rates compress biotech sector multiples broadly.
Minimal direct credit exposure as the company has no commercial lending operations or significant receivables. However, tighter credit conditions reduce availability of venture debt financing and can pressure institutional investors to reduce speculative biotech allocations, affecting stock liquidity and valuation multiples.
growth - Attracts speculative biotech investors focused on binary clinical trial outcomes and potential multi-bagger returns from FDA approval. The -41% three-month return and -66.1% ROA indicate this is a high-risk, high-reward profile suitable only for investors with tolerance for potential total loss. Not appropriate for value or income investors given no revenue, negative margins, and no dividend. Momentum traders may engage around clinical trial data catalysts.
high - Clinical-stage single-asset biotechs exhibit extreme volatility around binary events (trial readouts, FDA decisions). The recent -41% quarterly drawdown is typical for this profile. Expect 30-50% single-day moves on material clinical or regulatory announcements. Low market cap ($100M) and limited institutional ownership amplify volatility through thin trading liquidity.
